F A W Coumans1, C J M Doggen2, G Attard3, J S de Bono3, L W M M Terstappen4. 1. Department of Medical Cell BioPhysics, Faculty of Sciences and Technology, MIRA Research Institute, University of Twente. Electronic address: f.a.w.coumans@utwente.nl. 2. Department of Health Technology & Services Research, University of Twente, Enschede, The Netherlands. 3. Department of Drug Development Unit, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK. 4. Department of Medical Cell BioPhysics, Faculty of Sciences and Technology, MIRA Research Institute, University of Twente.
Abstract
BACKGROUND: Presence of five or more circulating tumor cells (CTC) in patients with metastatic carcinomas is associated with poor survival. Although many objects positive for epithelial cell adhesion molecules and cytokeratin (EpCAM+CK+) are not counted as CTC, they may be an important predictor for survival. We evaluated the association between these objects and survival in patients with prostate cancer. PATIENTS AND METHODS: Included in this follow-up study were 179 patients with castration-resistant prostate cancer. CellSearch was used to isolate EpCAM+ objects and to stain DNA, cytokeratin and CD45. All EpCAM+CK+ objects were subdivided into seven classes on the basis of predefined morphological appearance in 63 independent samples. Association of each class with survival was studied using Kaplan-Meier and Cox regression analyses. RESULTS: Each EpCAM+CK+CD45- class showed a strong association with overall survival (P < 0.001). This included small tumor microparticles (S-TMP), which did not require a nucleus and thus are unable to metastasize. A higher number of objects in any class was associated with decreased survival. A good prediction model included large tumor cell fragments (L-TCF), age, hemoglobin and lactate dehydrogenase. Models with S-TMP or CTC instead of L-TCF performed similarly. CONCLUSION: EpCAM+CK+CD45- that do not meet strict definitions for CTC are strong prognostic markers for survival.
BACKGROUND: Presence of five or more circulating tumor cells (CTC) in patients with metastatic carcinomas is associated with poor survival. Although many objects positive for epithelial cell adhesion molecules and cytokeratin (EpCAM+CK+) are not counted as CTC, they may be an important predictor for survival. We evaluated the association between these objects and survival in patients with prostate cancer. PATIENTS AND METHODS: Included in this follow-up study were 179 patients with castration-resistant prostate cancer. CellSearch was used to isolate EpCAM+ objects and to stain DNA, cytokeratin and CD45. All EpCAM+CK+ objects were subdivided into seven classes on the basis of predefined morphological appearance in 63 independent samples. Association of each class with survival was studied using Kaplan-Meier and Cox regression analyses. RESULTS: Each EpCAM+CK+CD45- class showed a strong association with overall survival (P < 0.001). This included small tumor microparticles (S-TMP), which did not require a nucleus and thus are unable to metastasize. A higher number of objects in any class was associated with decreased survival. A good prediction model included large tumor cell fragments (L-TCF), age, hemoglobin and lactate dehydrogenase. Models with S-TMP or CTC instead of L-TCF performed similarly. CONCLUSION:EpCAM+CK+CD45- that do not meet strict definitions for CTC are strong prognostic markers for survival.
Authors: Dena Marrinucci; Kelly Bethel; Anand Kolatkar; Madelyn S Luttgen; Michael Malchiodi; Franziska Baehring; Katharina Voigt; Daniel Lazar; Jorge Nieva; Lyudmila Bazhenova; Andrew H Ko; W Michael Korn; Ethan Schram; Michael Coward; Xing Yang; Thomas Metzner; Rachelle Lamy; Meghana Honnatti; Craig Yoshioka; Joshua Kunken; Yelena Petrova; Devin Sok; David Nelson; Peter Kuhn Journal: Phys Biol Date: 2012-02-03 Impact factor: 2.583
Authors: Chad V Pecot; Farideh Z Bischoff; Julie Ann Mayer; Karina L Wong; Tam Pham; Justin Bottsford-Miller; Rebecca L Stone; Yvonne G Lin; Padmavathi Jaladurgam; Ju Won Roh; Blake W Goodman; William M Merritt; Tony J Pircher; Stephen D Mikolajczyk; Alpa M Nick; Joseph Celestino; Cathy Eng; Lee M Ellis; Michael T Deavers; Anil K Sood Journal: Cancer Discov Date: 2011-11-03 Impact factor: 39.397
Authors: Ja Hye Myung; Michael J Eblan; Joseph M Caster; Sin-Jung Park; Michael J Poellmann; Kyle Wang; Kevin A Tam; Seth M Miller; Colette Shen; Ronald C Chen; Tian Zhang; Joel E Tepper; Bhishamjit S Chera; Andrew Z Wang; Seungpyo Hong Journal: Clin Cancer Res Date: 2018-03-15 Impact factor: 12.531
Authors: Jeffrey B Smerage; G Thomas Budd; Gerald V Doyle; Marty Brown; Costanza Paoletti; Maria Muniz; M Craig Miller; Madeline I Repollet; David A Chianese; Mark C Connelly; Leon W W M Terstappen; Daniel F Hayes Journal: Mol Oncol Date: 2013-03-14 Impact factor: 6.603
Authors: Chun-Liang Chen; Devalingam Mahalingam; Pawel Osmulski; Rohit R Jadhav; Chiou-Miin Wang; Robin J Leach; Tien-Cheng Chang; Steven D Weitman; Addanki Pratap Kumar; Luzhe Sun; Maria E Gaczynska; Ian M Thompson; Tim Hui-Ming Huang Journal: Prostate Date: 2012-12-31 Impact factor: 4.104